Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$13.74
+1.2%
$14.39
$6.99
$17.75
$1.64B1.872.28 million shs457,267 shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$14.46
+3.4%
$15.24
$10.60
$38.12
$1.52B0.361.18 million shs301,734 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$7.08
+0.4%
$9.85
$6.53
$30.60
$61.60M2.89145,905 shs8,476 shs
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$6.22
+2.8%
$6.79
$4.25
$16.74
$960.72M-0.921.29 million shs237,757 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-3.96%-1.31%-6.54%+6.09%+52.93%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-2.30%-4.11%-10.78%-46.99%-18.47%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-2.49%-8.44%-24.27%-51.58%-62.08%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
+1.85%+0.17%-11.42%-42.71%-1.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.3221 of 5 stars
3.41.00.00.04.01.70.6
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
3.2788 of 5 stars
4.42.00.00.03.13.30.0
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.8742 of 5 stars
2.91.00.04.62.00.80.0
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
4.3618 of 5 stars
3.50.00.04.84.24.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$18.8036.83% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.78
Moderate Buy$40.22178.10% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.80
Reduce$73.67940.49% Upside
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
3.00
Buy$21.17240.30% Upside

Current Analyst Ratings Breakdown

Latest ARQT, EWTX, MCRB, and WVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
4/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$41.00
4/29/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/21/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.00
4/9/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/8/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/3/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$212.82M7.70N/AN/A$0.94 per share14.62
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.53 per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.33M0.49N/AN/A($0.35) per share-20.23
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$104.94M9.14N/AN/A$0.40 per share15.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$100.16M-$1.55N/AN/AN/AN/A-26.83%-25.67%8/14/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%8/14/2025 (Estimated)

Latest ARQT, EWTX, MCRB, and WVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.45-$0.43+$0.02-$0.43N/AN/A
5/8/2025Q1 2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million
3/4/2025Q4 2024
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.17$0.17+$0.34$0.17$25.60 million$83.75 million
3/3/2025Q4 2024
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.39-$0.42-$0.03-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.67
2.46
2.38
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
26.35
26.35
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.12
1.12
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/A
1.90
1.90

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
89.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.20 million105.93 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.20 million71.86 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million162.03 millionOptionable
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
240154.13 million108.14 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$13.74 +0.16 (+1.18%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$14.46 +0.47 (+3.38%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$7.08 +0.03 (+0.43%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wave Life Sciences stock logo

Wave Life Sciences NASDAQ:WVE

$6.22 +0.17 (+2.81%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.